174 related articles for article (PubMed ID: 11334239)
1. Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models.
Rogóz Z; Kłodzińska A; Maj J
Pol J Pharmacol; 2000; 52(6):459-62. PubMed ID: 11334239
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the discriminative stimulus effects of the D3 dopamine antagonist PNU-99194A in rats: comparison with psychomotor stimulants.
Baker LE; Miller ME; Svensson KA
Behav Pharmacol; 1997 Jun; 8(2-3):243-52. PubMed ID: 9833019
[TBL] [Abstract][Full Text] [Related]
3. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
[TBL] [Abstract][Full Text] [Related]
4. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.
Gyertyán I; Sághy K
Behav Pharmacol; 2004 Jul; 15(4):253-62. PubMed ID: 15252275
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes.
Sheppard B; Lehmann J; Cope ZA; Brown RW
Behav Neurosci; 2009 Dec; 123(6):1296-308. PubMed ID: 20001113
[TBL] [Abstract][Full Text] [Related]
7. Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a: an analysis of possible mechanisms.
Goudie AJ; Baker LE; Smith JA; Prus AJ; Svensson KA; Cortes-Burgos LA; Wong EH; Haadsma-Svensson S
Behav Pharmacol; 2001 Sep; 12(5):303-15. PubMed ID: 11710745
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach.
Clifford JJ; Waddington JL
Psychopharmacology (Berl); 1998 Apr; 136(3):284-90. PubMed ID: 9566814
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Banasikowski TJ; Beninger RJ
Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
[TBL] [Abstract][Full Text] [Related]
10. The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys.
Claytor R; Lile JA; Nader MA
Pharmacol Biochem Behav; 2006 Mar; 83(3):456-64. PubMed ID: 16631246
[TBL] [Abstract][Full Text] [Related]
11. Effects of the putative dopamine D3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C57BL/6J mice.
Gendreau PL; Petitto JM; Schnauss R; Frantz KJ; Van Hartesveldt C; Gariépy JL; Lewis MH
Eur J Pharmacol; 1997 Oct; 337(2-3):147-55. PubMed ID: 9430408
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
[TBL] [Abstract][Full Text] [Related]
13. Acute neurobehavioral effects of toluene: involvement of dopamine and NMDA receptors.
Lo PS; Wu CY; Sue HZ; Chen HH
Toxicology; 2009 Nov; 265(1-2):34-40. PubMed ID: 19765629
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model.
Rogóz Z; Skuza G; Kłodzińska A
Pol J Pharmacol; 2003; 55(3):449-54. PubMed ID: 14506325
[TBL] [Abstract][Full Text] [Related]
15. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist.
Kłodzińska A; Tatarczyńska E; Stachowicz K; Chojnacka-Wójcik E
J Physiol Pharmacol; 2004 Mar; 55(1 Pt 1):113-26. PubMed ID: 15082872
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of anxiolytics and beta-receptor blocking drugs on novelty-oriented ("neophobic") behavior in the rat.
Delini-Stula A; Hunn C
Pharmacopsychiatry; 1988 Jul; 21(4):186-91. PubMed ID: 2905063
[TBL] [Abstract][Full Text] [Related]
18. The D3 antagonist PNU-99194A potentiates the discriminative cue produced by the D3 agonist 7-OH-DPAT.
Depoortere R; Perrault G; Sanger DJ
Pharmacol Biochem Behav; 2000 Jan; 65(1):31-4. PubMed ID: 10638632
[TBL] [Abstract][Full Text] [Related]
19. The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E
J Pharm Pharmacol; 2005 Feb; 57(2):253-7. PubMed ID: 15720791
[TBL] [Abstract][Full Text] [Related]
20. Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats.
Braszko JJ; Wielgat P; Walesiuk A
Neuropeptides; 2008 Jun; 42(3):301-9. PubMed ID: 18359517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
